Open AccessEfficacy and Safety of Triamcinolone Injection in Keloid
Author(s) -
Saly El-Said Ayad,
Engi Saif Shaker,
Naglaa I. Sarhan,
Fatma Abd El-Ghaffar Abd rabo
Publication year - 2022
Publication title -
journal of advances in medicine and medical research
Language(s) - English
Resource type - Journals
ISSN - 2456-8899
DOI - 10.9734/jammr/2022/v34i331274
Subject(s) - triamcinolone acetonide , keloid , medicine , itching , dermatology , scars , surgery
Background: A keloid scar is characterised by the production of type III (early) or type I (late) collagen. The goal of this study was to see how effective intralesional triamcinolone acetonide was in treating Keloids from a clinical and microscopic standpoint.
Methods: This prospective study included 40 patients diagnosed clinically and histologically with Keloid. Patients were given intralesional injection of triamcinolone (40mg / ml) and each 1 cm2 of keloid was injected by 0.3 ml of the solution for one session monthly for five subsequent sessions. Patients were subjected to full history taking, clinical examination [general and dermatological], digital photography of the lesions and tissue punch biopsies.
Results: Before treatment: Normal pigmentation occurred in 36(90.0%) and hyper pigmentation occurred in 4(10.0%). After treatment: Normal pigmentation occurred in 32(80.0%), hyper and hypo pigmentation occurred in 4(10.0%). Colour, itching, pliability and surface area were insignificantly different before and after treatment.
Conclusions: The triamcinolone injection was to be promising and long lasting for the suppression of symptoms related to keloids and hypertrophic scars.